BioSpace News Archive

Genenta Science announces that it held its Ordinary and Extraordinary Shareholders’ Meeting on May 2, 2024.

Integra LifeSciences Holdings Corporation, a leading global medical technology company, reported financial results for the first quarter ending March 31, 2024.

Zomedica Corp., a veterinary health company offering point-of-care diagnostics and therapeutic products for equine and companion animals, announced that it has received CE certification for its VetGuardian® remote contactless monitoring system.

BioNTech SE reported financial results for the three months ended March 31, 2024, and provided an update on its corporate progress.

Agios Pharmaceuticals, Inc., a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, announced that the company is scheduled to present at the BofA Securities 2024 Health Care Conference on Thursday, May 16, 2024, at 11:40 a.m. ET.

Cara Therapeutics, Inc., a development-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, announced the Company will report first quarter 2024 financial results on Monday, May 13, 2024, after the U.S. markets close.

LSL PHARMA GROUP INC. is pleased to announce that it has entered into a binding Letter of Intent to acquire profitable privately held, Quebec-based competing contract drug manufacturer specialized in the formulation, production, and marketing of natural products .

Foghorn® Therapeutics Inc., a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, provided a financial and corporate update in conjunction with the Company’s 10-Q filing for the quarter ended March 31, 2024.

BioLineRx Ltd. announced that new economic model data will be presented on APHEXDA® for CD34+ hematopoietic stem cell mobilization in patients with multiple myeloma at the International Society for Pharmacoeconomics and Outcomes Research – The Professional Society for Health Economics and Outcomes Research – 2024 conference, taking place May 5-8, 2024, in Atlanta, Georgia.

Mediar Therapeutics, Inc. announced that, following FDA clearance of its investigational new drug application, the first cohort of participants has been dosed in a Phase 1 trial evaluating the safety and tolerability of MTX-463.